These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22464500)

  • 1. Regulatory crackdown on stem cell therapy: what would the position be in South Africa?
    Jordaan D
    S Afr Med J; 2012 Mar; 102(4):219-20. PubMed ID: 22464500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
    von Tigerstrom B
    Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The registration and control of medicines in South Africa: legal issues.
    Folb PI
    Med Law; 1991; 10(6):555-63. PubMed ID: 1822574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA challenges stem-cell clinic.
    Cyranoski D
    Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009
    [No Abstract]   [Full Text] [Related]  

  • 5. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States.
    Sipp D
    Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA's claims over stem cells upheld.
    Cyranoski D
    Nature; 2012 Aug; 488(7409):14. PubMed ID: 22859178
    [No Abstract]   [Full Text] [Related]  

  • 7. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
    Doua JY; Van Geertruyden JP
    Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future development of global regulations of Chinese herbal products.
    Fan TP; Deal G; Koo HL; Rees D; Sun H; Chen S; Dou JH; Makarov VG; Pozharitskaya ON; Shikov AN; Kim YS; Huang YT; Chang YS; Jia W; Dias A; Wong VC; Chan K
    J Ethnopharmacol; 2012 Apr; 140(3):568-86. PubMed ID: 22373513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rejuvenating Regenerative Medicine Regulation.
    Charo RA; Sipp D
    N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
    [No Abstract]   [Full Text] [Related]  

  • 10. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions.
    Turner L
    Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA regulation of stem-cell-based therapies.
    Halme DG; Kessler DA
    N Engl J Med; 2006 Oct; 355(16):1730-5. PubMed ID: 17050899
    [No Abstract]   [Full Text] [Related]  

  • 12. From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
    Knoepfler PS
    Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emergence and popularisation of autologous somatic cellular therapies in Australia: therapeutic innovation or regulatory failure?
    McLean AK; Stewart C; Kerridge I
    J Law Med; 2014 Sep; 22(1):65-89. PubMed ID: 25341320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA regulation of adult stem cell therapies as used in sports medicine.
    Chirba MA; Sweetapple B; Hannon CP; Anderson JA
    J Knee Surg; 2015 Feb; 28(1):55-62. PubMed ID: 25603042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stem cells. U.S. regulation of stem cells as medical products.
    Sipp D; Turner L
    Science; 2012 Dec; 338(6112):1296-7. PubMed ID: 23224541
    [No Abstract]   [Full Text] [Related]  

  • 16. Autologous cell therapies: challenges in US FDA regulation.
    McAllister TN; Audley D; L'Heureux N
    Regen Med; 2012 Nov; 7(6 Suppl):94-7. PubMed ID: 23210819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identity and ownership issues in the regulation of autologous cells.
    Sipp D
    Regen Med; 2017 Oct; 12(7):827-838. PubMed ID: 29115180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global bionetworks and challenges in regulating autologous adult stem cells.
    Lysaght T; Kerridge I; Sipp D; Porter G; Capps BJ
    Am J Med; 2013 Nov; 126(11):941-3. PubMed ID: 24157285
    [No Abstract]   [Full Text] [Related]  

  • 20. Dual regulatory pharmaceutical labeling schemes; the role of the Federal Preemption Doctrine.
    Fern FH; Bartell L
    Health Matrix; 1987; 5(3):17-23. PubMed ID: 10285381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.